Home
Adimmune

Adimmune Market Share Analysis for November 2025

國光生物科技股份有限公司成立於1965年，為亞洲唯一獲得歐盟gmp認證與美國fda認證之流感疫苗製造公司，是台灣唯一符合最新pic/s gmp規範之人用疫苗生物製劑廠。主要產品有三價流感疫苗、四價流感疫苗、h1n1新型流感疫苗、日本腦炎疫苗、破傷風類毒素、結核菌淨素。

Health > Health Conditions and Concerns

Domainadimmune.com.tw

Year Founded1965

Employees501 - 1000

Annual Revenue$50M - $75M

Adimmune

Adimmune (including company regionals)

adimmune.com.tw

See more website traffic and engagement information

Adimmune Revenue up to November 2025 is 50M - 75M

revenue generated by Adimmune top domains

Adimmune top domains revenue over 3 years

Revenue for Adimmune top domains

adimmune.com.tw50M - 75M

See more with Sales Intelligence

Total visits to Adimmune's top domains

Understand Adimmune market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

adimmune.com.tw14.6K

See more with Sales Intelligence

Avg. visit duration in Adimmune's top domains

Analyze Adimmune engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

adimmune.com.tw00:03:37

See more with Sales Intelligence

Avg. pageviews on Adimmune's top domains

See how Adimmune keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

adimmune.com.tw2.11

See more with Sales Intelligence

Adimmune top competitors by domain

Top similar sites in November 2025, ranked by their affinity

oep.com.twCompany NameOrient EuroPharma Co., Ltd.Employees501 - 1000HQTaiwan, TaipeiAnnual revenue--Total visits14.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Adimmune

These are the website technologies, by industry, used by Adimmune top domains

Widget (3)

reCAPTCHA

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Mobile (2)

Meta Viewport

More Technologies

6

See all

News & Signals from Adimmune

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAdimmune Corporation launched candidate vaccine for the Wuhan coronavirus on May 1st '20.Taiwan-based vaccine maker Adimmune Corporation ( ) has announced that a candidate vaccine for the Wuhan coronavirus (COVID-19) could be ready for animal trials as soon as May.

NewsAdimmune Corporation is developing AdimrSC-2f vaccine (COVID-19 S-protein).The official approval from the FDA means Adimmune can begin testing its "AdimrSC-2f vaccine (COVID-19 S-protein)" on human participants, effective immediately, the FDA said.